tavapadon + carbamazepine

**tavapadon + carbamazepine** is a combination of two pharmaceutical agents:\n\n- **Tavapadon** is an investigational, orally administered small molecule acting as a partial agonist at the dopamine D1-like receptor subtypes D1 and D5. It is being developed primarily for the treatment of Parkinson’s disease, targeting motor symptoms by mimicking the action of dopamine in the brain. Tavapadon has shown promise in improving motor function with a favorable safety profile in Phase 3 clinical trials[1][3][5][7].\n\n- **Carbamazepine** is an established anticonvulsant and analgesic used in the treatment of epilepsy (various seizure types), trigeminal neuralgia (a neuropathic pain condition), and acute manic and mixed episodes in bipolar I disorder[2][4][6]. Carbamazepine acts by inhibiting voltage-gated sodium channels, stabilizing hyperexcited nerve membranes, suppressing repetitive neuronal firing, and decreasing synaptic transmission[4][6]. It is available in multiple oral formulations.\n\nThere is no known product or clinical trial specifically studying or marketing the fixed combination tavapadon + carbamazepine. Thus, this entry describes the expected properties based on the two constituent drugs.

Brand names

Carnexiv

Other names

tavapadoncarbamazepincarbamazepinacarbamazepinumCBZ